Thus, counteracting the impairment of CD8+ TILs and promoting a sustained tumor-cell-directed cytotoxic T-cell response are necessary to overcome such immunosuppression and to establish efficacious immunotherapeutic treatments in mGBM patients. Here, CD8A is linked to neoplasm.